Between April 1989 and December 1992, 38 patients with endometrial cancer who were at high risk for recurrence entered a prospective study designed to evaluate the efficacy of adjuvant platinum (cisplatin), adriamycin (doxorubicin), and cytoxan (cyclophosphamide) (PAC) chemotherapy. Patients received cisplatin (50 mg/m(2)) doxorubicin (30 mg/m(2)) and cyclophosphamide (500 mg/m(2)) at 3-week intervals for 2-3 cycles. All patients completed the treatment, there were no life-threatening adverse events. The median duration of follow-up was 52.9+/-16.9 months. Six patients developed a recurrence, and 4 of them died after a median interval of 45.5 months. Five of the six patients with recurrence had stage IIIc disease. The 3-year progression-free survival was 83.3%, the overall survival rate was 89.2%. Results suggest that adjuvant chemotherapy with PAC may reduce the incidence of recurrence and improve the survival rate of patients with endometrial cancer.

Related Articles